Literature DB >> 9824689

Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration.

J D Oh1, D S Russell, C L Vaughan, T N Chase, D Russell.   

Abstract

Sensitization of striatal N-methyl-D-aspartate receptors (NMDAR) has been linked to events leading to the motor response changes associated with the administration of dopaminomimetics to parkinsonian animals and patients. To determine whether tyrosine phosphorylation of NMDAR subunits contributes to the apparent long-term enhancement in synaptic efficacy of these receptors, we examined the effect of unilateral nigrostriatal dopamine system ablation with 6-hydroxydopamine followed by twice-daily treatment with l-DOPA on the phosphorylation state of rat striatal NR2A and NR2B subunits. Three weeks of intermittent l-DOPA administration produced a shortening in the duration of the rotational response to dopaminergic challenge and other changes mimicking those occurring in patients with Parkinson's disease. Concurrently, tyrosine phosphorylation of NR2A and especially of NR2B subunits increased ipsilateral to the lesion (20+/-5% and 46+/-7% of intact striatum, respectively; p<0.01) without attendant changes in subunit protein levels. Selective blockade of NR2B subunits with ACEA 10-1244, but not of NR2A subunits with MDL 100,453, reversed the l-DOPA-induced response alterations. The intrastriatal injection of a tyrosine kinase inhibitor, genistein, at a dose (2.0 microg) that normalized the response shortening, attenuated the NR2A and NR2B phosphorylation increase by about 12% and 24%, respectively (p<0.01). Taken together, these results suggest that augmented tyrosine phosphorylation of NR2B subunits, alone or in combination with the smaller rise in NR2A subunit phosphorylation, contributes to the apparent enhancement in striatal NMDAR sensitivity and thus to the plastic alterations in dopaminergic responses in l-DOPA-treated parkinsonian rats. Copyright 1998 Published by Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824689     DOI: 10.1016/s0006-8993(98)01049-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  30 in total

1.  A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease.

Authors:  J E Nash; J M Brotchie
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Neurobehavioural deficits following postnatal iron overload: I spontaneous motor activity.

Authors:  A Fredriksson; N Schröder; T Archer
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

3.  Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking.

Authors:  Penelope J Hallett; Robert Spoelgen; Bradley T Hyman; David G Standaert; Anthone W Dunah
Journal:  J Neurosci       Date:  2006-04-26       Impact factor: 6.167

Review 4.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

5.  Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.

Authors:  A Fredriksson; W Danysz; G Quack; T Archer
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

6.  The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease.

Authors:  John E Kelsey; Caroline Neville
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

7.  The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.

Authors:  Sara Sanz-Blasco; Melina P Bordone; Ana Damianich; Gimena Gomez; M Alejandra Bernardi; Luciana Isaja; Irene R Taravini; Diane P Hanger; M Elena Avale; Oscar S Gershanik; Juan E Ferrario
Journal:  Mol Neurobiol       Date:  2017-08-24       Impact factor: 5.590

Review 8.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 9.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

Review 10.  Striatal glutamatergic mechanisms and extrapyramidal movement disorders.

Authors:  Thomas N Chase; Francesco Bibbiani; Justin D Oh
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.